These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35018250)

  • 1. Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies.
    Hsu WF; Wang HW; Chen CK; Lai HC; Chuang PH; Tsai MH; Su WP; Chen HY; Chu CS; Chou JW; Chen SH; Tsai TY; Hsiao WD; Lin CC; Huang GT; Lin JT; Peng CY
    Am J Cancer Res; 2021; 11(12):6173-6187. PubMed ID: 35018250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy.
    Hsu WF; Lai HC; Chen CK; Wang HW; Chuang PH; Tsai MH; Chen SH; Chu CS; Su WP; Chou JW; Kao JT; Chen HY; Chuang SC; Tsai TY; Hsiao WD; Huang GT; Peng CY
    Am J Cancer Res; 2023; 13(2):654-668. PubMed ID: 36895987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience.
    Hsu WF; Chuang PH; Chen CK; Wang HW; Tsai MH; Su WP; Chen HY; Yang CY; Lin CC; Huang GT; Lin JT; Lai HC; Peng CY
    Am J Cancer Res; 2020; 10(12):4547-4560. PubMed ID: 33415018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.
    Shao YY; Liu TH; Hsu C; Lu LC; Shen YC; Lin ZZ; Cheng AL; Hsu CH
    Liver Int; 2019 Nov; 39(11):2184-2189. PubMed ID: 31400295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Assessment of Nomogram Based on AFP Response for Patients with Unresectable Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors.
    Zhang Y; Shen H; Zheng R; Sun Y; Xie X; Lu MD; Liu B; Huang G
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.
    Tian BW; Yan LJ; Ding ZN; Liu H; Meng GX; Xue JS; Han CL; Dong ZR; Hong JG; Chen ZQ; Wang DX; Li T
    Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):73-83. PubMed ID: 36476076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
    Pinato DJ; Li X; Mishra-Kalyani P; D'Alessio A; Fulgenzi CAM; Scheiner B; Pinter M; Wei G; Schneider J; Rivera DR; Pazdur R; Theoret MR; Casak S; Lemery S; Fashoyin-Aje L; Cortellini A; Pelosof L
    JHEP Rep; 2023 Jun; 5(6):100747. PubMed ID: 37197442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma.
    Lee PC; Chao Y; Chen MH; Lan KH; Lee CJ; Lee IC; Chen SC; Hou MC; Huang YH
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31940757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
    Teng W; Lin CC; Su CW; Lin PT; Hsieh YC; Chen WT; Ho MM; Wang CT; Chai PM; Hsieh JC; Lin CY; Lin SM
    Am J Cancer Res; 2022; 12(4):1899-1911. PubMed ID: 35530282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy.
    Luo MC; Wu JY; Wu JY; Lin ZT; Li YN; Zeng ZX; Wei SM; Yan ML
    J Hepatocell Carcinoma; 2023; 10():1827-1837. PubMed ID: 37850079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
    Wang R; Lin N; Mao B; Wu Q
    J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma.
    Kim HI; Lim J; Shim JH
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):2069-2077. PubMed ID: 34459972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.
    Han CL; Tian BW; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Tan SY; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
    Cancer Immunol Immunother; 2023 Jul; 72(7):1957-1969. PubMed ID: 36811662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor.
    Lin PT; Hsu YC; Kao YT; Teng W; Hsieh YC; Chen WT; Su CW; Wang CT; Chai PM; Lin CC; Lin CY; Lin SM
    Am J Cancer Res; 2024; 14(3):1306-1315. PubMed ID: 38590407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
    Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
    Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic Changes of Neutrophil-to-Lymphocyte Ratio on Predicting Response of Immune Checkpoint Inhibitors Plus Targeted Therapies for Unresectable Hepatocellular Carcinoma.
    Yang J; Zhang Y; Chen Y; Yang Y; Deng Y
    J Hepatocell Carcinoma; 2024; 11():1495-1505. PubMed ID: 39131510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.
    Zhang J; Wang L; Zhang S; Cao R; Zhao Y; Zhao Y; Song Y; Guo Z
    BMC Cancer; 2024 Feb; 24(1):266. PubMed ID: 38408930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan.
    Wu JS; Hong TC; Wu HT; Lin YJ; Chang TT; Wang CT; Liu WC; Hsieh MT; Wu IC; Chen PJ; Chen CY; Lin SH; Chuang CH; Han MZ; Chen HP; Tsai HM; Kuo HY
    J Gastrointest Oncol; 2023 Apr; 14(2):849-862. PubMed ID: 37201085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.